Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data
Résumé
The 300IR house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is approved for treatment of HDM-induced allergic rhinitis (AR). To provide a comprehensive review of the 300IR HDM-SLIT tablet safety profile based on randomized controlled trial (RCT) pooled data and post-marketing (PM) pharmacovigilance data.
Origine | Publication financée par une institution |
---|---|
licence |